CAMP Latest News, Press Relases and Analysis

All

Press Releases

21 hours ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 hours ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

9 days ago - By: CAMP4 Therapeutics

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

9 days ago - By: CAMP4 Therapeutics

CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights

3 months ago - By: The Motley Fool

Camp4 Reports Q2 Revenue Beats Estimates

7 months ago - By: Benzinga - Mentions: GNFT EWTX

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

2 months ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

2 months ago - By: CAMP4 Therapeutics

CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01

2 months ago - By: Benzinga - Mentions: KEQU BLRX VNRX RNA ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

2 months ago - By: CAMP4 Therapeutics

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

2 months ago - By: CAMP4 Therapeutics

CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders

3 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

3 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

6 months ago - By: CAMP4 Therapeutics

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

6 months ago - By: CAMP4 Therapeutics

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American

6 months ago - By: CAMP4 Therapeutics

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

6 months ago - By: CAMP4 Therapeutics

CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights

7 months ago - By: CAMP4 Therapeutics

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

7 months ago - By: CAMP4 Therapeutics

CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting

8 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

8 months ago - By: CAMP4 Therapeutics

CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update

8 months ago - By: CAMP4 Therapeutics

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

8 months ago - By: CAMP4 Therapeutics

CAMP4 Appoints Multiple Industry Veterans to its Board of Directors

9 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in Upcoming Investor Conferences

9 months ago - By: CAMP4 Therapeutics

CAMP4 to Participate in Upcoming Investor Conferences

10 months ago - By: CAMP4 Therapeutics

CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference

10 months ago - By: CAMP4 Therapeutics

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

10 months ago - By: CAMP4 Therapeutics

CAMP4 THERAPEUTICS CORP (CAMP) Stock News

CAMP Latest News, Press Relases and Analysis